Number of Thalidomide Victims in US Vastly Underreported, Lawsuit Claims
SEATTLE – New research suggests that thalidomide - a drug that caused thousands of horrific cases of deformities in children - caused far more deformities in the U.S. than were reported during the height of the pharmaceutical crisis of the early 1960s.
Invented by German drug company Grunenthal, thalidomide was widely used throughout Europe during the late 1950s and early 1960s, resulting in thousands of deaths and extreme, disfiguring birth defects when used by women during pregnancy. The drug was never approved in the United States, but the new lawsuit filed today by law firm Hagens Berman alleges that as many as 2.5 million doses of the drug were distributed by more than 1,200 doctors to more than 20,000 people, including pregnant women.
The lawsuit claims that conclusions made in the early 1960s about the types of birth defects caused by the drug were incorrect.
According to Berman, researchers concluded that thalidomide causes bilateral birth defects, such as two missing or shortened arms or hearing loss in both ears. As a result, babies born with unilateral defects, such as one deformed limb, or hearing loss in only one ear were not deemed thalidomide victims, even when their mothers were given the drug while pregnant.
However, new research involving thalidomide as part of a treatment regimen in cancer patients show that many of the assumptions used in the 1960s are incorrect.
"We think that many individuals who suffered severe birth defects and who thought they were merely the victim of nature, may have actually been injured by thalidomide," Berman said. "We now believe that there could be hundreds of individuals in the United States who suffered severe birth defects as a result of thalidomide, but were incorrectly diagnosed at birth."
The lawsuit alleges that this new understanding of thalidomide means that many individuals who experienced unilateral defects may have been misdiagnosed when their doctors told them thalidomide could not have been the cause.
"Among other things we intend to show in court that thalidomide does not work through a neural mechanism as previously thought, but affects the vascular system," Berman added.
This is especially relevant for one of the plaintiffs named in the complaint, Philip "Hook" Yeatts, a professional race car driver who competes in the U.S. Legends Series. Yeatts was born without his right arm or right leg, a severely curved spine and a deformed tongue. He overcame his disability, competing in a modified car and rising through the ranks to become a professional driver.
Yeatts' mother suffered from morning sickness during pregnancy and was given
thalidomide by her doctor, according to the complaint.
Yeatts would never have been considered a victim of thalidomide because the predominant medical view held that thalidomide could not cause unilateral injuries like his.
The complaint claims that the defendants are guilty of negligence in distributing the drug.
The firm is continuing to research the case. Those with additional information or who believe they might have suffered as a result of in utero thalidomide exposure are encouraged to call Hagens Berman at 206-623-7292 or email the firm at Thalidomide@hbsslaw.com.
More information about the case can be found at www.hbsslaw.com/cases/thalidomide.
# # #
About Hagens Berman
Hagens Berman Sobol Shapiro LLP is a consumer-rights class-action law firm with offices in nine cities. The firm has been named to the National Law Journal’s Plaintiffs’ Hot List seven times. More about the law firm and its successes can be found at www.hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.